Alrizomadlin

SKU: orb1707648

Description

Alrizomadlin (APG-115) is an orally bioavailable MDM2-p53 interaction inhibitor. It demonstrates potent, dose-dependent anti-proliferative activity in TP53 wild-type AML cell lines such as MOLM-13 and induces p53-dependent cell cycle arrest and apoptosis, supporting its investigation in cancer research.

Research Area

Cell Biology, Protein Biochemistry

Images & Validation

−

Key Properties

−

CAS Number	1818393-16-6
MW	642.59
Purity	99.47% (May vary between batches)
Formula	C₃₄H₃₈Cl₂FN₃O₄
SMILES	CCN1[C@H]([C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc23)C11CCCCC1)C(=O)NC12CCC(CC1)(CC2)C(O)=O
Target	Apoptosis,MDM-2/p53,E1/E2/E3 Enzyme,Mdm2
Solubility	10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (7.78 mM);DMSO:81.67 mg/mL (127.1 mM)

Bioactivity

−

Target IC50	MDM2:3.8 nM
In Vivo	METHODS: APG-115 was orally administered to TRP53-/- knockout C57BL/6J mice at 10 or 50 mg/kg daily or every other day (Q2D) to observe the effect of APG-115 on tumor growth in mice. RESULTS APG-115 can effectively activate the p53 pathway, affect macrophage polarization (reduce M2 type, increase M1 type), and increase PD-L1 expression on tumor cells, regulate the immune microenvironment, and enhance anti-tumor immune response. METHODS: APG-115 was administered to mice orally (PO), 20 mg/kg, once every two days for 21 days; daily administration: 50 mg/kg, for 7 days; daily administration changes High dose: 100 mg/kg for 7 days to observe the in vivo therapeutic effect of APG-115. RESULTS Administration of APG-115 significantly reduced leukemia burden and prolonged survival in mice in the TP53 wild-type systemic MOLM-13 AML model. Compared with the control group, the median survival time of the APG-115 treatment group was extended by approximately 18.5 days. Read more...
In Vitro	METHODS: CD4 T cells isolated from mouse spleen were exposed to 250 nM APG-115 for 3, 6, and 24 hours, and the effect of APG-115 on T cell viability and activation was investigated. RESULTS APG-115 treatment did not induce apoptosis of CD4+ T cells, but promoted CD4+ T cell activation, as evidenced by an increase in the proportion of CD25highCD62Llow cells and an increase in cell size. In addition, treatment did not lead to an increase in the number of regulatory T cells (Tregs), demonstrating a positive activation effect on effector T cells. METHODS: Different concentrations of APG-115 (0.001-100μM) were used to treat TP53wt AML cell lines, including MOLM-13, MV-4-11, OCI-AML-3, and HL-60 and SKM-1 cells with TP53 mutations or deletions. , the treatment time is 72 hours, and cell viability, cell cycle and apoptosis analysis are detected. RESULTS APG-115 showed significant dose-dependent inhibitory effect on TP53wt AML cell line, with IC50 values of 26.8 nM for MOLM-13 cells, 165.9 nM for MV-4-11 cells, and 315.6 nM for OCI-AML-3 cells; APG -115 treatment caused a significant increase in the proportion of MOLM-13 cell apoptosis, reaching a maximum of 96.8% (1 μM concentration), and caused cell cycle arrest in the G0/G1 phase. Read more...

Storage & Handling

−

Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

AA 115, AA115, AA-115, APG 115, APG115, APG-115, Alrizomadlin, Mdm2

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

91972012 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

Alrizomadlin (orb1707648)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

Alrizomadlin

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

Alrizomadlin (orb1707648)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors